Aljian Capital Management LLC acquired a new stake in CVS Health Corporation (NYSE:CVS - Free Report) in the second quarter, according to the company in its most recent filing with the SEC. The firm acquired 13,176 shares of the pharmacy operator's stock, valued at approximately $1,363,000.
A number of other institutional investors and hedge funds have also bought and sold shares of CVS. Caitong International Asset Management Co. Ltd raised its position in shares of CVS Health by 407.2% during the third quarter. Caitong International Asset Management Co. Ltd now owns 350 shares of the pharmacy operator's stock worth $26,000 after acquiring an additional 281 shares during the last quarter. Swiss RE Ltd. bought a new stake in shares of CVS Health during the 4th quarter valued at about $26,000. Sankala Group LLC bought a new stake in CVS Health in the fourth quarter worth approximately $28,000. Global Trust Asset Management LLC lifted its stake in CVS Health by 344.8% in the first quarter. Global Trust Asset Management LLC now owns 387 shares of the pharmacy operator's stock valued at $28,000 after buying an additional 300 shares during the period. Finally, Mcguire Capital Advisors Inc. acquired a new stake in shares of CVS Health during the 4th quarter worth approximately $28,000. 80.66% of the stock is currently owned by institutional investors and hedge funds.
Analysts Set New Price Targets
CVS has been the topic of a number of research reports. HSBC reaffirmed a "hold" rating and set a $103.00 price target on shares of CVS Health in a research note on Monday, July 6th. Morgan Stanley upped their target price on shares of CVS Health from $106.00 to $111.00 and gave the stock an "overweight" rating in a report on Thursday, June 4th. Robert W. Baird set a $107.00 price target on CVS Health in a research note on Thursday, August 6th. Royal Bank Of Canada increased their price target on CVS Health from $107.00 to $113.00 and gave the company an "outperform" rating in a research report on Thursday, July 9th. Finally, Mizuho upped their price objective on shares of CVS Health from $110.00 to $115.00 and gave the stock an "outperform" rating in a research report on Monday, June 8th. Twenty-two equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat, CVS Health currently has a consensus rating of "Moderate Buy" and an average price target of $106.75.
Get Our Latest Research Report on CVS Health
Insider Activity at CVS Health
In related news, Director Larry Robbins sold 370,462 shares of the business's stock in a transaction that occurred on Thursday, May 21st. The shares were sold at an average price of $93.45, for a total transaction of $34,619,673.90. Following the completion of the transaction, the director owned 4,824,799 shares of the company's stock, valued at approximately $450,877,466.55. The trade was a 7.13% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 0.85% of the company's stock.
Key Stories Impacting CVS Health
Here are the key news stories impacting CVS Health this week:
- Positive Sentiment: CVS reported strong second-quarter results, with earnings per share rising more than 40% year over year as profitability in its Health Care Benefits segment improved. The company also raised its 2026 adjusted operating income outlook, reinforcing the recovery story. CVS Q2 EPS Gains From Improved Health Care Benefits Profitability
- Positive Sentiment: CVS appointed Teresa Heitsenrether, JPMorgan’s data and analytics chief, to its board. Her technology, analytics and operating experience could support CVS’s artificial-intelligence and data initiatives, potentially improving efficiency and decision-making across its businesses. CVS adds JPMorgan data executive to board amid AI push
- Positive Sentiment: Brokerages assigned CVS an average “Moderate Buy” rating, reflecting improved earnings momentum and optimism about Aetna’s performance. CVS Health Given Average Rating of Moderate Buy
CVS Health Stock Up 0.9%
CVS opened at $94.87 on Wednesday. The company's 50-day moving average price is $102.41 and its two-hundred day moving average price is $88.56. CVS Health Corporation has a twelve month low of $69.51 and a twelve month high of $110.68. The stock has a market cap of $121.33 billion, a price-to-earnings ratio of 25.10, a PEG ratio of 0.93 and a beta of 0.61. The company has a quick ratio of 0.66, a current ratio of 0.87 and a debt-to-equity ratio of 0.74.
CVS Health (NYSE:CVS - Get Free Report) last issued its earnings results on Wednesday, August 5th. The pharmacy operator reported $2.58 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.87 by $0.71. The firm had revenue of $106.10 billion for the quarter, compared to analyst estimates of $100.03 billion. CVS Health had a return on equity of 13.12% and a net margin of 1.18%.The business's revenue was up 7.3% on a year-over-year basis. During the same period in the previous year, the company posted $1.81 earnings per share. CVS Health has set its FY 2026 guidance at 7.900-8.100 EPS. As a group, equities analysts expect that CVS Health Corporation will post 8.02 earnings per share for the current year.
CVS Health Dividend Announcement
The business also recently declared a quarterly dividend, which was paid on Monday, August 3rd. Stockholders of record on Thursday, July 23rd were given a dividend of $0.665 per share. The ex-dividend date was Thursday, July 23rd. This represents a $2.66 annualized dividend and a dividend yield of 2.8%. CVS Health's dividend payout ratio is currently 70.37%.
CVS Health Profile
(
Free Report)
CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.
Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.
Featured Stories
Want to see what other hedge funds are holding CVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CVS Health Corporation (NYSE:CVS - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider CVS Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CVS Health wasn't on the list.
While CVS Health currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
